Cargando…

Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009

To evaluate trends in and risk factors for acquisition of antimicrobial-drug resistant nontyphoidal Salmonella infections, we searched Oregon surveillance data for 2004–2009 for all culture-confirmed cases of salmonellosis. We defined clinically important resistance (CIR) as decreased susceptibility...

Descripción completa

Detalles Bibliográficos
Autores principales: Barlow, Russell S., DeBess, Emilio E., Winthrop, Kevin L., Lapidus, Jodi A., Vega, Robert, Cieslak, Paul R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3966386/
https://www.ncbi.nlm.nih.gov/pubmed/24655581
http://dx.doi.org/10.3201/eid2004.131063
_version_ 1782308904413167616
author Barlow, Russell S.
DeBess, Emilio E.
Winthrop, Kevin L.
Lapidus, Jodi A.
Vega, Robert
Cieslak, Paul R.
author_facet Barlow, Russell S.
DeBess, Emilio E.
Winthrop, Kevin L.
Lapidus, Jodi A.
Vega, Robert
Cieslak, Paul R.
author_sort Barlow, Russell S.
collection PubMed
description To evaluate trends in and risk factors for acquisition of antimicrobial-drug resistant nontyphoidal Salmonella infections, we searched Oregon surveillance data for 2004–2009 for all culture-confirmed cases of salmonellosis. We defined clinically important resistance (CIR) as decreased susceptibility to ampicillin, ceftriaxone, ciprofloxacin, gentamicin, or trimethoprim/sulfamethoxazole. Of 2,153 cases, 2,127 (99%) nontyphoidal Salmonella isolates were obtained from a specific source (e.g., feces, urine, blood, or other normally sterile tissue) and had been tested for drug susceptibility. Among these, 347 (16%) isolates had CIR. The odds of acquiring CIR infection significantly increased each year. Hospitalization was more likely for patients with than without CIR infections. Among patients with isolates that had been tested, we analyzed data from 1,813 (84%) who were interviewed. Travel to eastern or Southeast Asia was associated with increased CIR. Isolates associated with outbreaks were less likely to have CIR. Future surveillance activities should evaluate resistance with respect to international travel.
format Online
Article
Text
id pubmed-3966386
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-39663862014-04-02 Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009 Barlow, Russell S. DeBess, Emilio E. Winthrop, Kevin L. Lapidus, Jodi A. Vega, Robert Cieslak, Paul R. Emerg Infect Dis Research To evaluate trends in and risk factors for acquisition of antimicrobial-drug resistant nontyphoidal Salmonella infections, we searched Oregon surveillance data for 2004–2009 for all culture-confirmed cases of salmonellosis. We defined clinically important resistance (CIR) as decreased susceptibility to ampicillin, ceftriaxone, ciprofloxacin, gentamicin, or trimethoprim/sulfamethoxazole. Of 2,153 cases, 2,127 (99%) nontyphoidal Salmonella isolates were obtained from a specific source (e.g., feces, urine, blood, or other normally sterile tissue) and had been tested for drug susceptibility. Among these, 347 (16%) isolates had CIR. The odds of acquiring CIR infection significantly increased each year. Hospitalization was more likely for patients with than without CIR infections. Among patients with isolates that had been tested, we analyzed data from 1,813 (84%) who were interviewed. Travel to eastern or Southeast Asia was associated with increased CIR. Isolates associated with outbreaks were less likely to have CIR. Future surveillance activities should evaluate resistance with respect to international travel. Centers for Disease Control and Prevention 2014-04 /pmc/articles/PMC3966386/ /pubmed/24655581 http://dx.doi.org/10.3201/eid2004.131063 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research
Barlow, Russell S.
DeBess, Emilio E.
Winthrop, Kevin L.
Lapidus, Jodi A.
Vega, Robert
Cieslak, Paul R.
Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009
title Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009
title_full Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009
title_fullStr Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009
title_full_unstemmed Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009
title_short Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009
title_sort travel-associated antimicrobial drug–resistant nontyphoidal salmonellae, 2004–2009
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3966386/
https://www.ncbi.nlm.nih.gov/pubmed/24655581
http://dx.doi.org/10.3201/eid2004.131063
work_keys_str_mv AT barlowrussells travelassociatedantimicrobialdrugresistantnontyphoidalsalmonellae20042009
AT debessemilioe travelassociatedantimicrobialdrugresistantnontyphoidalsalmonellae20042009
AT winthropkevinl travelassociatedantimicrobialdrugresistantnontyphoidalsalmonellae20042009
AT lapidusjodia travelassociatedantimicrobialdrugresistantnontyphoidalsalmonellae20042009
AT vegarobert travelassociatedantimicrobialdrugresistantnontyphoidalsalmonellae20042009
AT cieslakpaulr travelassociatedantimicrobialdrugresistantnontyphoidalsalmonellae20042009